The STAT report on the Science Translational Medicine paper highlights a key shift: HIV-infected CD4+ T cells can downregulate CD4 and upregulate CD8 via gene expression changes, creating a previously unrecognized reservoir. This observational lab study, based on samples from a modest cohort of Chinese patients (n=42), lacked randomization and relied on in vitro models, introducing potential selection bias without reported conflicts of interest from the team. Going deeper, this plasticity aligns with patterns in other persistent viruses like CMV and EBV, where infected cells evade detection by altering surface markers, suggesting HIV exploits similar immune evasion mechanisms across chronic infections. Prior reservoir research, such as the 1997 Chun et al. observational study in Nature (n=22 patients) identifying resting CD4+ memory cells, missed this CD8 transition entirely, leading to incomplete targeting in CRISPR-based trials like those reported in 2023 Lancet HIV. An additional 2021 RCT in Nature Medicine (n=60) on broadly neutralizing antibodies also overlooked CD8+ reservoirs, limiting efficacy. These gaps imply that long-term ART strategies must now incorporate CD8-specific immunotherapies to address viral persistence comprehensively, potentially extending timelines for functional cures by 5-10 years.